Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 06, 2019 09:00 ET | Source: BioBridge Global

BioBridge Global adds two industry leaders to Regenerative Medicine Advisory Board

San Antonio, Texas, May 06, 2019 (GLOBE NEWSWIRE) -- BioBridge Global has added two new members to its Regenerative Medicine Advisory Board, a group composed of industry leaders with a wide range of...
February 01, 2019 07:00 ET | Source: AVROBIO, Inc.

AVROBIO, Inc. Announces Time Change for Analyst and Investor Presentation and Webcast, now 5:30 p.m. ET on Wednesday, February 6, 2019

CAMBRIDGE, Mass., Feb. 01, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced a time change for its analyst and...
January 18, 2019 07:00 ET | Source: AVROBIO, Inc.

AVROBIO, Inc. Announces Acceptance of Investigational New Drug (IND) Application for Investigator-Sponsored Phase 1/2 Clinical Trial for AVR-RD-04 Gene Therapy for Cystinosis

CAMBRIDGE, Mass., Jan. 18, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”) a Phase 2 clinical-stage gene therapy company, today announced that its investigational gene therapy...
January 17, 2019 07:00 ET | Source: AVROBIO, Inc.

AVROBIO, Inc. Announces Analyst and Investor Event and Upcoming Clinical Data Presentations at WORLDSymposium 2019

CAMBRIDGE, Mass., Jan. 17, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced that clinical trial updates related...
January 07, 2019 07:06 ET | Source: AVROBIO, Inc.

AVROBIO, Inc. Appoints Philip J. Vickers to its Board of Directors

CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a clinical-stage gene therapy company, today announced the appointment of Philip J. Vickers, Ph.D.,...
December 21, 2018 10:00 ET | Source: AVROBIO, Inc.

AVROBIO, Inc. Added to NASDAQ Biotechnology Index

CAMBRIDGE, Mass., Dec. 21, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO), (“The Company”) a Phase 2 clinical-stage gene therapy company, today announced that the Company has been selected...
December 19, 2018 07:00 ET | Source: AVROBIO, Inc.

AVROBIO Receives Orphan-Drug Designation from the U.S. FDA for AVR-RD-01 for the Treatment of Fabry Disease

CAMBRIDGE, Mass., Dec. 19, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ:AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company developing gene therapies to potentially cure rare...
December 18, 2018 07:05 ET | Source: AVROBIO, Inc.

AVROBIO, Inc. Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Dec. 18, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO), (“The Company”) a Phase 2 clinical-stage gene therapy company, today announced the grant of non-qualified stock...
December 18, 2018 07:00 ET | Source: AVROBIO, Inc.

AVROBIO, Inc. Expands and Strengthens Leadership Team with Four Senior Management Hires

CAMBRIDGE, Mass., Dec. 18, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO), (“The Company”) a Phase 2 clinical-stage gene therapy company, today announced the appointment of four key senior...
November 13, 2018 08:00 ET | Source: AVROBIO, Inc.

AVROBIO, Inc. Reports Third Quarter 2018 Financial Results and Provides Business Update

During the quarter, announced updated Fabry clinical data, acceptance of Clinical Trial Application for Gaucher, and continued platform optimization CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE...

Next Page keyboard_arrow_right